{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:22:23Z","timestamp":1792416143019,"version":"4.4.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rare FGF23-producing mesenchymal tumors lead to paraneoplastic tumor-induced osteomalacia (TIO) presenting with phosphate wasting, hypophosphatemia, chronic hypomineralization of the bone, fragility fractures and muscle weakness. Diagnosis of TIO requires exclusion of other etiologies and careful search for a mesenchymal tumor that often is very small and can appear anywhere in the body. Surgical removal of the tumor is the only definitive treatment of TIO. Surgical complications due to chronic hypophosphatemia are not well recognized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Description<\/jats:title><jats:p>The current case describes severe fragility fractures in a 58-year-old woman, who lost her ability to walk and was bedridden for two years. First, the initial diagnostic laboratory work-up did not include serum phosphorus measurements, second, the suspicion of adverse effects of pioglitazone as an underlying cause delayed correct diagnosis for at least two years. After biochemical discovery of hyperphosphaturic hypophosphatemia at a tertiary referral centre, a FGF23-producing tumor of the mandible was discovered on physical examination, and then surgically removed. Postoperatively, severe hypophosphatemia and muscle weakness prolonged the need for ventilation support, intensive care and phosphate supplementation. After two years of rehabilitation, the patient was able to walk short distances. The tumor has not recurred, and serum phosphate concentration has remained within normal limits during 3.5 years of follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The case report illustrates knowledge gaps in the diagnostic work-up of rare causes of low bone mass and fragility fractures. Compared to other low phosphate conditions, surgical recovery from TIO-induced hypophosphatemia warrants special attention. Increased alkaline phosphatase concentration may indicate impaired postsurgical recovery due to prolonged hypophosphatemia, underlining the need for proactive perioperative correction of hypophosphatemia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.686135","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T17:18:39Z","timestamp":1622740719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Eeva M.","family":"Ryh\u00e4nen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Schalin-J\u00e4ntti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Matikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-Induced Osteomalacia","volume":"7","author":"Florenzano","year":"2017","journal-title":"Bone Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e10436","DOI":"10.1002\/jbm4.10436","article-title":"Burden of Disease in Patients With Tumor-Induced Osteomalacia","volume":"5","author":"Jerkovich","year":"2020","journal-title":"JBMR Plus"},{"key":"B3","first-page":"1871","article-title":"Tumor-Induced Osteomalacia","volume":"7","author":"Kumar","year":"2015","journal-title":"Transl Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4274\/jcrpe.2017.S008","article-title":"Genetic Causes of Rickets","volume":"9","author":"Acar","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0849-5","article-title":"Phosphaturic Mesenchymal Tumors: What an Endocrinologist Should Know","volume":"41","author":"Boland","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001652","article-title":"Pharmacological Therapy for the Prevention and Treatment of Weakness After Critical Illness: A Systematic Review","volume":"44","author":"Shepherd","year":"2016","journal-title":"Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1881","article-title":"Tumor Localization and Biochemical Response to Cure in Tumor-Induced Osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2018.03.005","article-title":"Bone Histomorphometry in the Evaluation of Osteomalacia","volume":"8","author":"Bhan","year":"2018","journal-title":"Bone Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05369-1","article-title":"Long-Term Bone Mineral Density Changes After Surgical Cure of Patients With Tumor-Induced Osteomalacia","volume":"31","author":"Colangelo","year":"2020","journal-title":"Osteoporos Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to Patients With Hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0076-3","article-title":"Role of Phosphate Sensing in Bone and Mineral Metabolism","volume":"14","author":"Chande","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198508153130705","article-title":"Effect of Hypophosphatemia on Diaphragmatic Contractility in Patients With Acute Respiratory Failure","volume":"313","author":"Aubier","year":"1985","journal-title":"N Engl J Med"},{"key":"B13","article-title":"Association of Hypophosphatemia With Failure-to-Wean From Mechanical Ventilation","volume":"40","author":"Alsumrain","year":"2010","journal-title":"Ann Clin Lab Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0148607115621863","article-title":"Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (a.s.P.E.N.)","volume":"40","author":"McClave","year":"2016","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjaed\/mkw033","article-title":"Phosphate Homeostasis in Critical Care","volume":"16","author":"Wadsworth RL","year":"2016","journal-title":"BJA Educ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011273032203","article-title":"Hypophosphatemia and Glucose Intolerance: Evidence for Tissue Insensitivity to Insulin","volume":"303","author":"DeFronzo","year":"1980","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2006.04839.x","article-title":"Hypophosphataemia Causing Profound Cardiac Failure After Cardiac Surgery","volume":"61","author":"Heames","year":"2006","journal-title":"Anaesthesia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/cc9215","article-title":"Treatment of Hypophosphatemia in the Intensive Care Unit: A Review","volume":"14","author":"Geerse","year":"2010","journal-title":"Crit Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 Processing in Fibrous Dysplasia","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2012.26.5.1113","article-title":"Perioperative Concerns in Patients With Tumor-Induced Osteomalacia for Surgical Excision of Tumor","volume":"32","author":"Pandey","year":"2012","journal-title":"Ann Saudi Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.aat.2012.07.002","article-title":"Anesthesia for Oncogenic Osteomalacia\u2013a Rare Paraneoplastic Syndrome","volume":"50","author":"Ramachandran","year":"2012","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_57_17","article-title":"Perioperative Management of Patients With Severe Hypophosphataemia Secondary to Oncogenic Osteomalacia: Our Experience and Review of Literature","volume":"61","author":"Verma","year":"2017","journal-title":"Indian J Anaesth"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2106","article-title":"In Vivo Assessment of Bone Quality in Postmenopausal Women With Type 2 Diabetes","volume":"29","author":"Farr","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01225.x","article-title":"Rosiglitazone and Pioglitazone Increase Fracture Risk in Women and Men With Type 2 Diabetes","volume":"12","author":"Aubert","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2668-0","article-title":"Hospitalised Hip Fracture Risk With Rosiglitazone and Pioglitazone Use Compared With Other Glucose-Lowering Drugs","volume":"55","author":"Colhoun","year":"2012","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of Fracture With Thiazolidinediones: An Updated Meta-Analysis of Randomized Clinical Trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0746","article-title":"Bone is a Target for the Antidiabetic Compound Rosiglitazone","volume":"145","author":"Rzonca","year":"2004","journal-title":"Endocrinology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.04.015","article-title":"PGC1beta Mediates PPARgamma Activation of Osteoclastogenesis and Rosiglitazone-Induced Bone Loss","volume":"11","author":"Wei","year":"2010","journal-title":"Cell Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The Diagnostic Dilemma of Tumor Induced Osteomalacia: A Retrospective Analysis of 144 Cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European Guidance for the Diagnosis and Management of Osteoporosis in Postmenopausal Women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-Induced Osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in Localization of Tumor Causing Oncogenic Osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-Induced Osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2018.06.005","article-title":"Molecular Imaging in Diagnosis of Tumor-Induced Osteomalacia","volume":"48","author":"Yang","year":"2019","journal-title":"Curr Probl Diagn Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-Induced Osteomalacia: An Important Cause of Adult-Onset Hypophosphatemic Osteomalacia in China: Report of 39 Cases and Review of the Literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","article-title":"Reports of 17 Chinese Patients With Tumor-Induced Osteomalacia","volume":"35","author":"Yu","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.137","article-title":"Characterization of FN1\u2013FGFR1 and Novel FN1\u2013FGF1 Fusion Genes in a Large Series of Phosphaturic Mesenchymal Tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2019.07.012","article-title":"Burosumab in Tumor-Induced Osteomalacia: A Case Report","volume":"87","author":"Day","year":"2020","journal-title":"Joint Bone Spine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.686135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T17:18:46Z","timestamp":1622740726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.686135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":39,"alternative-id":["10.3389\/fendo.2021.686135"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.686135","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"article-number":"686135"}}